Anakinra is a recombinant IL-1 receptor inhibitor commonly used for the treatment of autoinflammatory diseases in rheumatology. Successful off-label use of anakinra has been reported in different cases of severe HS. Several reports, in addition to our case, show that patients’ selection remains important since not all patients with HS respond well to anti-IL1 therapy, and further clinical investigation is needed to help on the predictive response to the different biological treatments

José María LLamas

Ángela Ayen Rodríguez

Bárbara Cancela Díez

Marina Galvez Moreno

Ricardo Ruiz Villaverde

European journal of clinical pharmacy

European Journal of Clinical Pharmacy®, is a peer reviewed biomedical journal that publish papers related to clinical pharmacy, clinical pharmacology, pharmacoepidemiology, pharmacoeconomics, pharmacotherapy and clinical management in the following sections, not necessary included in every issue.

The European Journal of Clinical Pharmacy® is a peer-reviewed biomedical journal that publishes papers related to clinical pharmacy, clinical pharmacology, pharmacoepidemiology, pharmacoeconomics, pharmacotherapy, and clinical management. The journal covers various sections, which may not necessarily be included in every issue.

《European Journal of Clinical Pharmacy》是一本经过同行评审的生物医学期刊，发表与临床药学、临床药理学、药物流行病学、药物经济学、药物治疗和临床管理相关的论文。期刊的内容涵盖多个领域，具体内容可能在每期中有所不同。

Hidradenitis suppurativa and anakinra

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info